|
Résumé :
|
[BDSP. Notice produite par INIST eYiQR0xu. Diffusion soumise à autorisation]. To have the "power'of avoiding undersized clinical trials, the customary statistical strategy used in the past few decades is aimed at rejecting both a null stochastic hypothesis and a contradictory alternative hypothesis. This approach gives a trial the" power'to confirm the "insignificance'of differences much smaller than the large value of delta desired in trials done to show efficacy, In many instances, however, a prime problem is that the current" double-significance'approach produces sample sizes 2-3 times larger than needed for stochastic confirmation of large differences ( delta). The inflated sample sizes and consequent problems can be avoided if a realistic value for delta is chosen and maintained thereafter, and if an adequate "capacity'is calculated for" single significance. ".
|